Search
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnAncrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. Currently, Viprinex®/ancrod is not approved or marketed in any country, ...
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus
Guanosine-5'-Monophosphate
go.drugbank.com/drugs/DB01972ExperimentalA guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. [PubChem]
Uridine monophosphate
go.drugbank.com/drugs/DB03685InvestigationalA uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.
Zinc gluconate
go.drugbank.com/drugs/DB11248ApprovedInvestigationalVet approvedZinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement a...
Mixtures: DAILY-ONE 45 FILM TABLET, Swiss One Timed Release TabLevomefolic acid
go.drugbank.com/drugs/DB11256ApprovedLevomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma . It is transported across the m...
Mixtures: Obtrex One, Obstetrix ONETyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Mixtures: INYECCIÓN DE TRAVASOL 10 % SIN ELECTROLITOS, TRAVASOL® SOLUCION BAL 8.5% SIN ELECTROLITOSRemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022].
Dibromothymoquinone
go.drugbank.com/drugs/DB04646ExperimentalAt higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]
Cagrilintide
go.drugbank.com/drugs/DB18887InvestigationalCagrilintide is under investigation in clinical trial NCT06221969 (A Research Study to See How Much Cagrisema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated